2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. (Q47973074)

7 February 2018

title

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. (English)

1 reference

7 February 2018

1 reference

25

Jose Baselga

1 reference

7 February 2018

15

Luca Gianni

1 reference

7 February 2018

Michael Untch

14

Michael Untch

1 reference

7 February 2018

13

Mitch Dowsett

1 reference

7 February 2018

4

Evandro de Azambuja

1 reference

7 February 2018

Aron Goldhirsch

1

Aron Goldhirsch

1 reference

7 February 2018

Marion Procter

5

Marion Procter

1 reference

7 February 2018

Herceptin Adjuvant (HERA) Trial Study Team

26

Herceptin Adjuvant (HERA) Trial Study Team

1 reference

7 February 2018

Christian Jackisch

7

Christian Jackisch

1 reference

7 February 2018

author name string

Richard D Gelber

2

1 reference

7 February 2018

Martine J Piccart-Gebhart

3

1 reference

7 February 2018

Thomas M Suter

6

1 reference

7 February 2018

David Cameron

8

1 reference

7 February 2018

Harald A Weber

9

1 reference

7 February 2018

Dominik Heinzmann

10

1 reference

7 February 2018

Lissandra Dal Lago

11

1 reference

7 February 2018

Eleanor McFadden

12

1 reference

7 February 2018

Richard Bell

16

1 reference

7 February 2018

Claus-Henning Köhne

17

1 reference

7 February 2018

Anita Vindevoghel

18

1 reference

7 February 2018

Michael Andersson

19

1 reference

7 February 2018

A Murray Brunt

20

1 reference

7 February 2018

Douglas Otero-Reyes

21

1 reference

7 February 2018

Santai Song

22

1 reference

7 February 2018

Ian Smith

23

1 reference

7 February 2018

Brian Leyland-Jones

24

1 reference

7 February 2018

language of work or name

English

0 references

publication date

18 July 2013

1 reference

7 February 2018

published in

The Lancet

1 reference

7 February 2018

volume

382

1 reference

7 February 2018

page(s)

1021-1028

1 reference

7 February 2018

issue

9897

1 reference

7 February 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961094-6

7 January 2021

10.1016/S0140-6736(13)61094-6

Identifiers

DOI

1 reference

7 February 2018

release_vwwsicislbg5lpwugfcnqgobki

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vwwsicislbg5lpwugfcnqgobki

24 November 2022

mapped directly with Wikidata item

PubMed ID

23871490

1 reference

7 February 2018